Press Room

bonus 1a

Wednesday, 22 November 2023 06:31

First Israeli Company Distinguished as a Global Leader in the Cell and Gene Therapy Industry

Bonus Biogroup Recognized Among Top Four Companies in Cell Therapy Biotech Innovation at Advanced Therapies Week 2024 in Miami, Florida

Bonus Biogroup is proud to announce its selection as one of the top four global leaders in cell therapy innovation, a remarkable distinction among hundreds of biotechnology companies [1]. This prestigious recognition will be formally presented at the Advanced Therapies Awards during Advanced Therapies Week, the premier annual international event of the cell and gene therapy industry, scheduled for January 16-19, 2024, in Miami, Florida [2].

Advanced Therapies Week is a pivotal gathering that unites companies from the cell and gene therapy industry worldwide. It focuses on presenting innovative treatments and products in advanced development stages and exploring collaborations for their commercialization [3].

Ahead of Advanced Therapies Week 2024, Bonus Biogroup has been lauded for its significant achievements in developing two groundbreaking products in advanced clinical trials: MesenCure, a cell therapy designed to treat inflammation and tissue damage, including pneumonia and respiratory distress, and BonoFill™, a live tissue-engineered human bone graft intended for bone tissue regeneration and rehabilitation. This is the first time an Israeli company has achieved this level of recognition by a distinguished judging panel representing the cell and gene therapy industry.

Advanced Therapies Week emphasizes the commercial viability of advanced therapies, highlighting the cost savings for healthcare systems and the medical benefits for patients. Specifically:

  • Economic Benefits: MesenCure potentially reduces hospitalization costs by about 40%, while BonoFill™ may cut surgery and hospitalization expenses by nearly half [4].
  • Patient Benefits: Clinical trials have shown that MesenCure may significantly decrease mortality rates in severe pneumonia and respiratory distress cases. BonoFill, which eliminates the need for a complex surgical procedure, facilitates the natural integration of the bone graft with the patient's body, potentially accelerating healing and expediting the return to normal functioning.

Advanced Therapies Week has been a premier gathering for twenty years, attracting thousands of leaders from the pharmaceutical, biopharma, and biotechnology industries, as well as international institutional and private investors specializing in advanced therapies. The world's leading companies are selected by a panel of eminent scientists, entrepreneurs, and CEOs from industry and academia [5].

Dr. Shai Meretzki, CEO of Bonus Biogroup, remarked, "Being chosen by the judging panel as one of the four foremost companies in biotechnology innovation in the cell and gene therapy industry is an affirmation of our leadership in developing innovative, life-changing, affordable, and commercially viable advanced therapies. We extend our gratitude to the conference organizers and the judging panel for this esteemed recognition."

About Bonus Biogroup

Bonus Biogroup Ltd. is a clinical-stage biotechnology company dedicated to developing advanced therapies in tissue regeneration and biotech products using tissue engineering and cell therapy. The Company currently has two products in clinical development: BonoFill™, a live tissue-engineered human bone graft intended for bone tissue regeneration and rehabilitation, and MesenCure, a cell therapy designed to treat inflammation and tissue damage, including pneumonia and respiratory distress. Bonus Biogroup also maintains a variety of technologies and products in the preclinical development phase.

The development of these products involves the application of unique technologies and knowledge proprietary to Bonus Biogroup. The Company's robust intellectual property portfolio includes six families of patents and patent applications, comprised of twenty-eight approved patents and fifteen patent applications, spanning numerous countries worldwide.

About BonoFill™ – Living Human Bone Graft

Bonus Biogroup has announced results from twenty out of thirty bone grafts in Phase II clinical trial for treating facial bone deficiencies, following a six-month observation period after each transplantation. The Company has completed the recruitment of all participants and is conducting a multicenter Phase II clinical trial to treat critical-sized bone defects in limb, hand, or foot bones at five medical centers in Israel using BonoFill™.

Bone deficiencies can arise due to aging, infections, osteoarthritis, traumas, and tumors. To mitigate the risk of rejection, Bonus Biogroup developed a living human bone graft using cells sampled from the patient. This lab-grown bone ensures effective bone grafts are readily available for various medical needs, including oral and maxillofacial surgery, skull surgery, orthopedic surgery, and plastic surgery, where bone tissue is lacking.

About the drug MesenCure

Bonus Biogroup has completed a Phase II clinical trial for treating pneumonia and life-teetering respiratory distress in severe COVID-19 patients using the cell therapy drug MesenCure. Clinical trial results indicate that MesenCure reduced the mortality rate of severe COVID-19 patients by 68% compared to the control group, with the survival rate standing at 94% for the 50 severe patients treated with the drug.

MesenCure, comprised of professionalized mesenchymal cells, aims to treat inflammation and tissue damage, including pneumonia and respiratory distress caused by the coronavirus or other viruses, bacterial infections, or other sources of immune overactivity, inflammation, or tissue damage.

The drug's effectiveness is attributed to the professionalization of the comprising cells, which enhances their natural ability to heal inflammation and tissue damage. The cells constituting MesenCure also affect inflammation and promote tissue regeneration through various mechanisms, potentially offering a broader and superior effect on diverse populations suffering from inflammation and tissue damage from multiple causes compared to drugs with a single mechanism of action.

Given the successful demonstration of MesenCure's effectiveness in treating acute respiratory distress in severe COVID-19 patients, the Company has broadened its efforts to investigate the potential efficacy of the drug and its derivatives in treating other indications such as cytokine release syndrome resulting from immunotherapy treatments to activate the immune system against cancer or from hematopoietic stem cell transplantation, as well as in tissue rehabilitation and healing.

Company Estimations Regarding Forward-Looking Statements

Bonus BioGroup's assessments regarding the medical effect and/or commercial potential of its products and/or the resulting economic opportunities, and the Company's ability to continue the process of their development, including conducting studies, and arriving at a product that can be medically applied in humans, for the duration and expected dates to perform any stage in any experiment and publish its results and obtain regulatory approvals for marketing the product, are forward-looking statements, as defined by the Securities Law of 1968, which are based on the Company's estimates and on the information in its possession at the time of reporting.

There is no certainty that these estimates will materialize, in whole or in part, among others, due to dependence on the actions of third parties, which are not under the Company's control, on the development of future cancer therapies, on future studies results, if any, due to the possibility of delay in obtaining approval from relevant authorities and/or change in the relevant conditions and/or feasibility tests that the Company may conduct and/or delay in performing studies and/or need to perform further experiments and/or failure of experiments and/or technological changes and/or the development and/or marketing of similar and/or more efficient competing products and/or the lack of resources and/or the realization of any of the risk factors associated with the research and/or studies and/or its results.

Sincerely,

Bonus BioGroup Ltd.

By: Yossi Rauch (Chairman of the Board) and Dr. Shai Meretzki (CEO and Director)

References

  1. Advanced Therapies Awards Finalists: https://advancedtherapiesawards.phacilitate.com/finalists/
  2. Advanced Therapies Week Homepage: https://advancedtherapiesweek.phacilitate.com/
  3. About Advanced Therapies Week: https://advancedtherapiesweek.phacilitate.com/why-advanced-therapies-week/
  4. For detailed information, refer to the Immediate Report dated July 11, 2023 (Company Presentation, reference: 2023-01-078258), incorporated herein by reference.
  5. Judges at the Advanced Therapies Awards: https://advancedtherapiesawards.phacilitate.com/judges/
Last modified on Wednesday, 22 November 2023 06:33

INFORMATION FOR INVESTORS  |  CAREER OPPORTUNITIES  |  INFORMATION FOR PATIENTS   |   RESEARCH COLLABORATIONS & BUSINESS DEVELOPMENT INQUIRIES

INFORMATION FOR INVESTORS

CAREER OPPORTUNITIES

INFORMATION FOR PATIENTS

RESEARCH COLLABORATIONS & BUSINESS DEVELOPMENT INQUIRIES

MAIL ICON  info@bonus-bio.com

MAIL ICON  +972 (0)73 206 7104

MAIL ICONMatam Advanced Technology
Park P.O.B 15143 Haifa 31905 Israel

you tube linkedin facebook twitter

© 2022 Bonus BioGroup Ltd. Created By Netron Israel Ltd

Please publish modules in offcanvas position.